10-K: Geron Reports Reduced Losses, RYTELO Sales Growth Amidst Legal Challenges

Geron Corporation reported a significant reduction in net losses for 2025, driven by initial RYTELO sales, while navigating ongoing legal proceedings and a strategic workforce reduction.

Summary

• Geron Corporation, a commercial-stage biopharmaceutical company, reported a net loss of $83.5 million for the year ended December 31, 2025, a substantial improvement from a net loss of $174.6 million in 2024.
• Product revenue from RYTELO (imetelstat) reached $183.6 million in 2025, up from $76.5 million in 2024, following its U.S. FDA approval in June 2024 for lower-risk Myelodysplastic Syndromes (MDS).
• The European Commission (EC) also approved RYTELO in March 2025 for adults with transfusion-dependent anemia due to lower-risk MDS, with commercialization in select EU markets planned for 2026 through third-party partners.
• The Phase 3 IMpactMF clinical trial for relapsed/refractory myelofibrosis (MF) completed enrollment in September 2025, with interim overall survival (OS) analysis expected in the second half of 2026 and final analysis in the second half of 2028.
• A strategic restructuring plan was implemented in December 2025, resulting in a workforce reduction of approximately one-third, with associated charges of $17.0 million.
• The company maintains a cash, cash equivalents, restricted cash, and marketable securities balance of $401.1 million as of December 31, 2025.
• Geron is facing securities class action and derivative lawsuits alleging false and misleading statements regarding RYTELO's commercial potential, with a motion to dismiss hearing scheduled for March 19, 2026.
• The Pharmakon Loan Agreement was amended in January 2026, extending the availability of Tranche B ($75.0 million) and Tranche C ($50.0 million) loans until July 30, 2026, subject to certain conditions including a revenue milestone for Tranche C.
• A new sales agreement (2026 Sales Agreement) with TD Cowen was entered into in February 2026, allowing for the issuance and sale of common stock up to $150 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing. While the significant reduction in net loss and initial RYTELO sales are encouraging, the variability in sales, ongoing litigation, and workforce reduction introduce notable uncertainties and risks.

Positives

• Net loss significantly decreased to $83.5 million in 2025 from $174.6 million in 2024, indicating improved financial performance.
• Product revenue from RYTELO increased substantially to $183.6 million in 2025 from $76.5 million in 2024, demonstrating initial commercial success.
• RYTELO received FDA approval in June 2024 and EC approval in March 2025 for lower-risk MDS, expanding its market reach.
• The IMpactMF Phase 3 clinical trial for relapsed/refractory MF completed enrollment in September 2025, moving closer to potential label expansion.
• RYTELO is positioned as a Category 1 preferred option in second-line RS+/RSESA-eligible patients and a Category 2A treatment for first-line ESA-ineligible RS+/RSpatients in MDS NCCN Guidelines, with an update in October 2025 changing from azacitadine to imetelstat as the preferred option in first-line RSESA-ineligible patients.
• The company has a strong cash position of $401.1 million as of December 31, 2025, providing liquidity for ongoing operations and development.
• The Pharmakon Loan Agreement provides access to an additional $125.0 million in debt financing, extending the availability of Tranche B and C loans to July 30, 2026.

Negatives

• Despite reduced losses, the company continues to incur significant net losses, with an accumulated deficit of approximately $1.9 billion as of December 31, 2025.
• RYTELO sales trends have been variable, with net product revenue of $48.0 million in Q4 2025, $47.2 million in Q3 2025, and $49.0 million in Q2 2025, indicating inconsistent growth.
• A strategic restructuring plan in December 2025 resulted in a workforce reduction of approximately one-third, incurring $17.0 million in charges and potentially disrupting operations.
• The company has limited experience in commercializing an approved drug product, and its ability to sustain and scale commercial operations is unproven.
• RYTELO faces intense competition from existing and developing products for MDS and MF, which could impact its commercial viability.
• The company is subject to pricing and reimbursement regulations in the EU, which may materially affect its ability to commercialize and receive reimbursement coverage for RYTELO.
• Ongoing securities class action and derivative lawsuits allege false and misleading statements concerning RYTELO's commercial potential, which are costly to defend and divert management attention.

Risks

• Near-term prospects are wholly dependent on RYTELO, and failure to successfully commercialize it in the U.S. for lower-risk MDS or expand its indication would materially and adversely affect revenue and profitability.
• Limited experience with commercialization of RYTELO in the U.S. and no experience outside the U.S. may lead to unsuccessful or less successful commercialization efforts.
• Competition from existing products, product candidates, and technologies, some of which may be deemed superior or more cost-effective than RYTELO, could significantly impact its commercial viability.
• Inability to maintain regulatory approvals for RYTELO in the U.S. and EU for lower-risk MDS, or delays in obtaining approvals for other indications/jurisdictions, could severely affect business.
• RYTELO is subject to post-marketing requirements and commitments, and failure to comply could lead to penalties or product withdrawal.
• Relationships with healthcare providers and promotional activities are subject to anti-kickback, fraud and abuse, and other healthcare laws, with non-compliance risking criminal sanctions, civil penalties, and reputational harm.
• RYTELO may cause undesirable or unintended side effects or adverse events, which could halt commercialization, delay regulatory approval, or terminate clinical trials.
• Results from prior non-clinical studies and clinical trials, including interim analyses, may not predict success in later clinical trials or final analyses, potentially impacting future regulatory approvals.
• Failure to maintain a manufacturing supply chain for RYTELO could adversely affect commercialization and delay or cease clinical trials.
• History of net losses and uncertainty in achieving consistent future profitability, requiring significant revenue generation.
• Failure to obtain additional capital, if and when needed, would force delays, reductions, or elimination of RYTELO development or commercialization.
• Indebtedness and debt service obligations under the Pharmakon Loan Agreement could adversely affect financial condition and limit operating flexibility.
• Inability to obtain and maintain sufficient intellectual property protection and regulatory exclusivities for RYTELO could allow competitors to commercialize similar products.
• Strategic restructuring plan and workforce reduction may not result in anticipated savings, could incur greater costs than expected, and disrupt business operations.
• Securities class action and derivative lawsuits are costly to defend, could result in substantial damages, and divert management's time and attention.
• Exposure to U.S. and foreign export/import controls, sanctions, embargoes, anti-corruption, and anti-money laundering laws, with compliance potentially impairing competitiveness.
• Compromise of information technology systems or data, or those of third parties, could lead to regulatory investigations, litigation, fines, business disruptions, and reputational harm.
• Volatility in stock price due to various factors, including regulatory announcements, clinical trial results, financial performance, and litigation.
• Failure to maintain compliance with Nasdaq listing requirements could result in delisting, negatively impacting stock price and access to capital markets.
• Provisions in charter, bylaws, and Delaware law may inhibit potential acquisition bids, adversely affecting stock price or preventing stockholders from benefiting from takeovers.
• Changes in tax laws or regulations could adversely affect business, cash flow, financial condition, or results of operations.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited due to ownership changes or state-level suspensions.

Future Outlook

Geron plans to maximize RYTELO's commercial opportunity in lower-risk MDS by investing in U.S. commercial efforts, driving new patient starts, reinforcing treatment duration value, educating healthcare providers on safety management, and leveraging payor access. The company is also pursuing paths to make RYTELO available in the EU and other regions, preparing for a planned EU launch in 2026 through third-party partners. Development programs for imetelstat in other myeloid hematologic malignancies, including the Phase 3 IMpactMF trial (interim OS analysis expected H2 2026, final H2 2028), Phase 1 IMproveMF, Phase 2 IMpress, and Phase 1/2 IMAGINE trials, are ongoing. The company expects research and development expenses to decrease slightly in 2026 due to lower labor costs from the workforce reduction, partially offset by higher clinical trial costs. Selling, general, and administrative expenses are also expected to decrease in 2026 due to lower labor costs, partially offset by higher marketing costs. Interest expense is projected to increase due to the Pharmakon Loan Agreement. The company believes existing cash and anticipated RYTELO revenues will fund projected operating requirements for the foreseeable future, but acknowledges the need for additional funding if sales are below expectations or unforeseen events occur.

Management Comments

• Management believes that the high unmet need in lower-risk MDS and significant product differentiation, including observed benefit of RYTELO in difficult-to-treat sub-populations, as well as the favorable FDA label and NCCN Guidelines, position RYTELO to potentially compete for significant market segments in lower-risk MDS.
• Management believes that telomerase inhibition with imetelstat represents a novel mechanism of action with unique benefits in hematologic malignancies and potentially in other tumor types.
• Management believes that testing a lower dose regimen for IMpactMF would likely result in a lower median OS and would not result in a clinically meaningful reduction in toxicity, hence the decision not to add a third dosing arm.
• Management believes the improvement in bone marrow fibrosis, potential survival benefit, molecular data and correlations from IMbark provide strong evidence of the potential for disease modification with imetelstat, which would differentiate it from currently approved treatments for MF, if approved.
• Management believes that our quarterly and annual results of operations may be affected by a variety of factors, including the overall level of demand for RYTELO, coverage and reimbursement, gross-to-net adjustments, cost of sales, royalty payments, and investment in sales, marketing, and R&D.

Industry Context

StockSavvy.ai notes that Geron operates in the highly competitive and dynamic biopharmaceutical sector, characterized by rapidly advancing technologies and a strong emphasis on proprietary products. The approval of RYTELO in both the U.S. and EU positions it as a novel treatment in the lower-risk MDS market, where existing therapies include ESAs (e.g., Amgen's Procrit, Aranesp), immunomodulators (e.g., BMS's Revlimid), hypomethylating agents (e.g., BMS's Vidaza), and newer agents like BMS's Reblozyl. The update to NCCN Guidelines favoring imetelstat in certain first-line ESA-ineligible patients is a significant competitive advantage. In the relapsed/refractory MF space, where imetelstat is in Phase 3, current treatments include JAK inhibitors (e.g., Incyte's Jakafi, BMS's Inrebic, GSK's OJJAARA, Sobi's Vonjo), with no approved therapies for patients who fail JAK inhibitors, highlighting a high unmet medical need that Geron aims to address. The industry also faces increasing legislative and regulatory scrutiny on drug pricing and data privacy, which could impact commercialization and operational costs.

Comparison to Industry Standards

• RYTELO is the first and only FDA and EC approved telomerase inhibitor, offering a novel mechanism of action compared to existing therapies for lower-risk MDS such as erythropoiesis-stimulating agents (ESAs) like Epoetin alfa (Procrit) and Darbepoetin alfa (Aranesp) by Amgen, and luspatercept (Reblozyl) by BMS.
• In lower-risk MDS, RYTELO's efficacy in achieving meaningful and durable transfusion independence and activity across various patient subtypes (RS positive/negative, high/very high transfusion burden) differentiates it from current standards of care.
• The NCCN Guidelines include imetelstat as a Category 1 preferred option in second-line RS+/RSESA-eligible patients and a Category 2A treatment for first-line ESA-ineligible RS+/RSpatients, indicating strong clinical endorsement compared to other treatments like azacitadine (BMS's Vidaza) which was previously preferred in some segments.
• For relapsed/refractory MF, where no drug therapy is currently approved for patients failing JAK inhibitors, IMbark Phase 2 data suggested a median OS of 28.1 months for high-dose imetelstat, almost twice the reported median OS of 14-16 months in medical literature for best available therapies (BAT) post-JAK inhibitor failure. Comparative analyses with real-world data from Moffitt Cancer Center showed a median OS of 30.7 months for imetelstat-treated patients versus 12.0 months for BAT-treated patients, suggesting a potential survival benefit and disease-modifying activity that would differentiate it from existing JAK inhibitors like Jakafi (Incyte), Inrebic (BMS), OJJAARA (GSK), and Vonjo (Sobi).

Management Changes

Corporate Governance

Legal Proceedings

• Two putative securities class action lawsuits were filed in March 2025 (Dabestani v. Geron Corporation, et al. and Potvin v. Geron Corporation, et al.) alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. These lawsuits were consolidated into In re Geron Corporation Securities Litigation, alleging that the company overstated RYTELO's commercial potential through materially false and misleading statements and/or concealment of material adverse facts.
• Three purported stockholder derivative complaints were filed in April 2025 (Bishop v. Scarlett, et al., Lerner v. Scarlett, et al., and Willis v. Scarlett, et al.) naming current and former directors and officers, alleging breach of fiduciary duties and violation of federal securities laws based on similar allegations as the securities class actions. These were consolidated into In re Geron Corporation Derivative Litigation and stayed pending a final ruling on the motion to dismiss in the Securities Class Action.
• An additional derivative lawsuit (Jae Hyung v. Bir, et al.) was filed in October 2025 by a purported stockholder with similar allegations, after the board deferred a decision on a demand to commence a civil action.
• The company intends to vigorously defend against these claims, but the lawsuits are costly, time-consuming, and could result in substantial damages or settlements, diverting management's attention and potentially impacting financial condition and stock price.

Stakeholder Impact

• **Shareholders:** Potential for dilution from future equity raises (2026 Sales Agreement, increased equity plan reserves). Stock price volatility is a significant risk. Ongoing litigation could lead to substantial damages or settlements, negatively impacting shareholder value. However, RYTELO's commercial success and pipeline progress could drive long-term value.
• **Employees:** Workforce reduction in December 2025 (approximately one-third of staff) impacts employee morale and job security. Changes in management (new CEO, CCO, EVP R&D) could affect company culture and strategic direction. New equity plans and competitive compensation aim to attract and retain talent.
• **Customers (Healthcare Providers & Patients):** RYTELO's FDA and EC approvals provide new treatment options for lower-risk MDS patients. Patient support programs (REACH4RYTELO) aim to improve access and affordability. However, potential side effects, monitoring requirements, and reimbursement challenges could affect patient access and physician adoption.
• **Suppliers & Creditors:** Reliance on third-party manufacturers and distributors creates supply chain risks. The Pharmakon Loan Agreement and Royalty Pharma Agreement impose debt service obligations and restrictive covenants, impacting financial flexibility. Failure to meet revenue milestones could affect access to additional debt tranches.

Next Steps

• Execute on U.S. commercial efforts for RYTELO, focusing on driving new patient starts, reinforcing treatment duration, educating HCPs on safety, and leveraging payor access.
• Pursue paths to make RYTELO available to eligible LR-MDS patients outside the U.S., including planned commercialization in select EU markets in 2026 through third-party partners.
• Progress development programs for imetelstat in other myeloid hematologic malignancies, including the Phase 3 IMpactMF trial (interim OS analysis expected H2 2026, final H2 2028).
• Continue to evaluate imetelstat as a combination therapy in the Phase 1 IMproveMF clinical trial for frontline myelofibrosis.
• Continue investigator-led Phase 2 IMpress clinical trial in higher-risk MDS and AML, and Phase 1/2 IMAGINE clinical trial in relapsed/refractory AML.
• Identify lead compounds for a potential next-generation oral telomerase inhibitor through a discovery program.
• Monitor and manage the ongoing securities class action and derivative lawsuits, with a motion to dismiss hearing scheduled for March 19, 2026.
• Potentially draw down Tranche B and Tranche C loans under the Pharmakon Loan Agreement by July 30, 2026, subject to conditions.
• Potentially issue and sell shares of common stock up to $150 million under the 2026 Sales Agreement with TD Cowen.
• Continue to assess the long-term safety of RYTELO in the extension phase of the IMerge trial and conduct a clinical trial to evaluate alternative dosing regimens in lower-risk MDS as post-marketing requirements.

Key Dates

Recommendation

Geron Corporation presents a mixed investment profile. The successful FDA and EC approvals of RYTELO for lower-risk MDS and its initial commercial launch are significant positives, demonstrating product validation and revenue generation. The ongoing Phase 3 IMpactMF trial for myelofibrosis offers substantial future growth potential. However, the company continues to incur net losses, RYTELO's sales growth is variable, and there are significant legal challenges (securities class action and derivative lawsuits) that could result in substantial costs and reputational damage. The recent workforce reduction, while aimed at improving financial discipline, signals operational challenges. While the company has a solid cash position and access to additional capital, the path to sustained profitability remains uncertain and subject to successful commercial execution, favorable clinical trial outcomes, and resolution of legal matters. A 'hold' recommendation is appropriate, reflecting the balance between promising product development and commercialization efforts against notable financial, operational, and legal risks.

Keywords

RYTELO, imetelstat, Geron Corporation, Myelodysplastic Syndromes, MDS, Myelofibrosis, MF, Telomerase Inhibitor, FDA Approval, EC Approval, Biopharmaceutical, Oncology, Clinical Trials, IMpactMF, Commercialization, Financial Results, Net Loss, Product Revenue, Workforce Reduction, SEC Filing, 10-K, Securities Litigation, Capital Raise, Debt Financing, Royalty Pharma